Recent advances in neuro-ophthalmology.
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
08
03
2024
accepted:
29
07
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
ppublish
Résumé
This review article represents a collaborative effort across continents, bringing together the latest developments in neuro-ophthalmology with a focus on innovative diagnostic and therapeutic modalities that are shaping the future of the field. Among the most significant advancements is the rise of optical coherence tomography (OCT), now recognized as an indispensable tool in neuro-ophthalmological research, providing unparalleled insights into optic nerve and central nervous system pathologies. Gene therapy, particularly for conditions such as Leber's hereditary optic neuropathy, marks a new frontier in personalized medicine, offering hope for previously untreatable conditions. The article also examines the transformative role of telemedicine and artificial intelligence (AI) in clinical practice, which are revolutionizing patient care and enhancing diagnostic precision. Furthermore, it highlights the impact of novel serological biomarkers on the understanding and management of immune-mediated optic neuritis, and discusses the introduction of new therapeutic agents like Tocilizumab and Teprotumumab, which are redefining treatment paradigms. Collectively, these advancements reflect the profound influence of modern medicine on neuro-ophthalmology, paving the way for improved patient outcomes and fostering new avenues for research and clinical practice.
Identifiants
pubmed: 39462921
doi: 10.4103/IJO.IJO_594_24
pii: 02223307-202472110-00006
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1544-1559Informations de copyright
Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.
Références
Bouma BE, de Boer JF, Huang D, Jang IK, Yonetsu T, Leggett CL, et al. Optical coherence tomography. Nat Rev Methods Primers 2022;2:79.
Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, et alO. C. T. Sub-Study Committee for NORDIC Idiopathic Intracranial Hypertension Study Group. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: Quality control, comparisons, and variability. Invest Ophthalmol Vis Sci 2014;55:8180–8.
Kaya Tutar N, Kale N. The relationship between lumbar puncture opening pressure and retinal nerve fiber layer thickness in the diagnosis of idiopathic intracranial hypertension: Is a lumbar puncture always necessary? Neurologist 2024;29:91–5.
Bassi ST, Pamu R, Ambika S, Praveen S, Priyadarshini D, Dharini V, et al. Optical coherence tomography in papilledema: A probe into the intracranial pressure correlation. Indian J Ophthalmol 2024;72:672–6.
Vijay V, Mollan SP, Mitchell JL, Bilton E, Alimajstorovic Z, Markey KA, et al. Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMAOphthalmol 2020;138:1264–71.
Wang JK, Kardon RH, Ledolter J, Sibony PA, Kupersmith MJ, Garvin MK, et al. Peripapillary retinal pigment epithelium layer shape changes from acetazolamide treatment in the idiopathic intracranial hypertension treatment trial. Invest Ophthalmol Vis Sci 2017;58:2554–65.
Li A, Tandon AK, Sun G, Dinkin MJ, Oliveira C. Early detection of optic nerve changes on optical coherence tomography using deep learning for risk-stratification of papilledema and glaucoma. J Neuroophthalmol 2024;44:47–52.
Bassi ST, Pamu R, Varghese A. Understanding pseudopapilledema on spectral domain optical coherence tomography. Indian J Ophthalmol 2023;71:3552–7.
Pratt L, Rehan S, West J, Watts P. Prevalence of peripapillary hyperreflective ovoid mass-like structures (PHOMS) in suspected papilloedema in children. Eye (Lond) 2023;37:3209–12.
Pramil V, Tam M, Vuong LN, Hedges TR 3rd. Upper limit of retinal nerve fibre layer thickness in patients with pseudopapilloedema. Neuroophthalmology 2022;46:390–8.
Girard MJA, Panda SK, Tun TA, Wibroe EA, Najjar RP, Aung T, et al. Discriminating between papilledema and optic disc drusen using 3D structural analysis of the optic nerve head. Neurology 2023;100:e192-202. doi: 10.1212/WNL.0000000000201350.
Malmqvist L, Bursztyn L, Costello F, Digre K, Fraser JA, Fraser C, et al. The optic disc drusen studies consortium recommendations for diagnosis of optic disc drusen using optical coherence tomography. J Neuroophthalmol 2018;38:299–307.
Leaney JC, Nguyen V, Miranda E, Barnett Y, Ahmad K, Wong S, et al. Bruch’s membrane opening minimum rim width provides objective differentiation between glaucoma and nonglaucomatous optic neuropathies. Am J Ophthalmol 2020;218:164–72.
Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999;40:2520–7.
Cerdá-Fuertes N, Stoessel M, Mickeliunas G, Pless S, Cagol A, Barakovic M, et al. Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis. Mult Scler 2023;29:1540–50.
Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Di Pauli F, et al. Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis. Neurology 2023;101:e784–93.
Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, et al. Retinal optical coherence tomography in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2021;8:e1068.
Song A, Johnson N, Ayala A, Thompson AC. Optical coherence tomography in patients with Alzheimer’s disease: What can it tell us? Eye Brain 2021;13:1–20.
Zhang Z, Kwapong WR, Cao L, Feng Z, Liu P, Wang R, et al. Correlation between serum biomarkers, brain volume, and retinal neuronal loss in early-onset Alzheimer’s disease. Neurol Sci 2024;45:2615–23.
Ibrahim Y, Xie J, Macerollo A, Sardone R, Shen Y, Romano V, et al. A Systematic review on retinal biomarkers to diagnose dementia from OCT/OCTA images. J Alzheimers Dis Rep 2023;7:1201–35.
Phuljhele S, Sharma S, Chawla R, Saxena R, Sharma P. Evaluation of optical coherence tomography angiography changes in nonarteritic anterior ischemic optic neuropathy. Indian J Ophthalmol 2023;71:2020–6.
Srivastava A. Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy. Mol Ther Nucleic Acids 2023;32:949–59.
Velmurugan S, Chou TH, Eastwood JD, Porciatti V, Liu Y, Hauswirth WW, et al. Comparison of different gene-therapy methods to treat Leber hereditary optic neuropathy in a mouse model. Front Neurosci 2023;17:1119724.
Sahel JA, Newman NJ, Yu-Wai-Man P, Vignal-Clermont C, Carelli V, Biousse V, et al. Gene therapies for the treatment of Leber hereditary optic neuropathy. Int Ophthalmol Clin 2021;61:195–208.
Wan X, Pei H, Zhao MJ, Yang S, Hu W, He H, et al. Efficacy and safety of rAAV2-ND4 treatment for Leber’s hereditary optic neuropathy. Sci Rep 2016;6:21587.
Yang S, Ma SQ, Wan X, He H, Pei H, Zhao M-J, et al. Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy. EBioMedicine 2016;10:258–68.
Yuan J, Zhang Y, Liu H, Wang D, Du Y, Tian Z, et al. Seven-year follow-up of gene therapy for Leber’s hereditary optic neuropathy. Ophthalmology 2020;127:1125–7.
Xiao S, Yuan J, Zhang Y, Zhang J, Tian Z, Liu H, et al. First China international gene therapy study in Leber hereditary optic neuropathy. Mol Ther 2020;28:558–9.
Liu H-L, Yuan J-J, Zhang Y, Tian Z, Li X, Wang D, et al. Factors associated with rapid improvement in visual acuity in patients with leber’s hereditary optic neuropathy after gene therapy. Acta Ophthalmol 2020;98:e730–3.
Feuer WJ, Schiffman JC, Davis JL, Porciatti V, Gonzalez P, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: Initial results. Ophthalmology 2017;123:558–70.
Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez P, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: Low- and medium-dose visual results. Ophthalmology 2017;124:1621–34.
Lam BL, Feuer WJ, Davis JL, Porciatti V, Yu H, Levy RB, et al. Leber hereditary optic neuropathy gene therapy: Adverse events and visual acuity results of all patient groups. Am J Ophthalmol 2022;241:262–71.
Vignal-Clermont C, Girmens J-F, Audo I, Said SM, Errera MH, Plaine L, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: The REVEAL study. BioDrugs 2021;35:201–14.
Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Trans Med 2020;12:eaaz7423.
Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology 2021;128:649–60.
Biousse V, Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Vignal-Clermont C, et al. Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: The RESTORE study. J Neuro-Ophthalmol 2021;41:309–15.
Newman NJ, Yu-Wai-Man P, Carelli V, Biousse V, Moster ML, Vignal-Clermont C, et al. Intravitreal gene therapy vs. natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>AND4 mutation: Systematic review and indirect comparison. Front Neurol 2021;12:662838.
Newman NJ, Yu-Wai-Man P, Subramanian PS, Moster ML, Wang AG, Donahue SP, et al. Randomized trial of bilateral gene therapy injection form.11778G>A MT-ND4 Leber optic neuropathy. Brain 2023;146:1328–41.
Carelli V, Newman NJ, Yu-Wai-Man P, Biousse V, Moster ML, Subramanian PS, et al. Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>A MT-ND4 mutation. Ophthalmol Ther 2023;12:401–29.
Vignal-Clermont C, Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, et al. Safety of lenadogene nolparvovec gene therapy over 5 years in 189 patients with Leber hereditary optic neuropathy. Am J Ophthalmol 2023;249:108–25.
Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G> A (MTND4) mitochondrial DNA mutation. J Neuroophthalmol 2020;40:547–57.
Calkins DJ, Yu-Wai-Man P, Newman NJ, Taiel M, Singh P, Chalmey C, et al. Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates. J Mol Ther Methods Clin Dev 2021;23:307–18.
Carelli V, Sadun A, Caporali L, Ross-Cisneros F, Boschetti E, Newman NJ, et al. Bilateral ocular post-mortem analyses in a patient with Leber hereditary optic neuropathy treated with unilateral AAV2 gene therapy. 11th European Meeting on Mitochondrial Pathology (EUROMIT) (Platform Presentation),Bologna, Italy, June 2023.
Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagrèze WA, et al. International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuro-Ophthalmol 2017;37:371–81.
Chinnery PF. Mitochondrial replacement in the clinic. N Engl J Med 2020;382:1855–7.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89.
Tajfirouz D, Padungkiatsagul T, Beres S, Moss HE, Pittock S, Flanagan E, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder. Mult Scler 2022;28:149–53.
Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci 2015;355:59–63.
Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurology-Neuroimmunol Neuroinflam 2019;6:e572.
Chen JJ, Flanagan EP, Pittock SJ, Stern NC, Tisavipat N, Bhatti MT, et al. Visual outcomes following plasma exchange for optic neuritis: An International multicenter retrospective analysis of 395 optic neuritis attacks. Am J Ophthalmol 2023;252:213–24.
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023. doi:10.1016/s1474-4422(22)00431-8.
Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 2018;195:8–15.
Chen JJ, Flanagan EP, Bhatti MT, Tisavipat N, Jamali S, Kunchok A, et al. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord 2022;68:104237.
Gravier-Dumonceau A, Ameli R, Rogemond V, Dutra LA, Hacohen Y, Kunchok A, et al. Glial fibrillary acidic protein autoimmunity: A Frenchcohort study. Neurology 2022;98:e653–68.
Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Boeve BF, et al. Glial fibrillary acidic protein immunoglobulin G as a biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017;81:298–309.
Chen JJ, Aksamit AJ, McKeon A, Lennon VA, Gadoth A, Echaniz-Laguna A, et al. Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuroophthalmol 2018;38:276–81.
Graus F, Vogrig A, Muñiz-Castrillo S, Ariño H, Dalmau J, Saiz A, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8:e1014.
Cohen DA, Bhatti MT, Pulido JS, Chen JJ, Kardon R, Flanagan EP, et al. Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema. Ophthalmology 2020;127:221–9.
Evoli A, Alboini PE, Damato V, Iorio R, Leone C, Muscia F, et al. Myasthenia gravis with antibodies to MuSK: An update. Ann N Y Acad Sci 2018;1412:82–9.
Rivner MH, Quarles BM, Pan JX, Zhu Y, Fan Z, Lee CS, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve 2020;62:333–43.
Klein CJ, Beecher G, Lamb C, Hinson SR, Pittock SJ, Schmitt SE, et al. LRP4-IgG service line testing in seronegative myasthenia gravis and controls. J Neuroimmunol 2022;368:577895.
Bohm PE, Chen JJ, Bhatti TM, Eggenberger ER, Flanagan EP, Fraunfelder FW, et al. Neuro-ophthalmic features of autoimmune encephalitides. J Neuroophthalmol 2020;40:385–97.
Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 2024;83:48–57.
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341–52.
Mollan SP, Fraser CL, Digre KB, Diener HC, Lipton RB, Juhler M, et al. Guidelines of the International Headache Society for controlled clinical trials in idiopathic intracranial hypertension. Cephalalgia 2023;43:3331024231197118.
Mollan SP, Paemeleire K, Versijpt J, Luqmani R, Sinclair AJ. European Headache Federation recommendations for neurologists managing giant cell arteritis. J Headache Pain. 2020 Mar 17;21(1):28.
Lee AG, Sinclair AJ, Sadaka A, Berry S, Mollan SP. Neuro-Ophthalmology: global trends in diagnosis, treatment and management. Springer; Switzerland; 2019.
Chen R, Zhang N, Gao L, Zhong Y, Xu L, Liu H, et al. Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis. Expert Opin Investig Drugs 2021;30:1231–40.
Aungsumart S, Youngkong S, Dejthevaporn C, Chaikledkaew U, Thadanipon K, Tansawet A, et al. Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. Front Neurol 2023;14:1166490.
Chang X, Zhang J, Li S, Wu P, Wang R, Zhang C, et al. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord 2023;72:104571.
Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 2022;11:e220189.
Piccus R, Thaller M, Sinclair AJ, Mollan SP, Mitchell JL, Kobeissi H, et al. Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension. Expert Rev Neurother 2023;23:457–66.
Westgate CSJ, Markey K, Mitchell JL, Yiangou A, Singhal R, Stewart P, et al. Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranialhypertension. Eur J Endocrinol 2022;187:323–33.
Markey KA, Ottridge R, Mitchell JL, Rick C, Woolley R, Ives N, et al. Assessing the efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH: DT: Clinical methods and design for a phase II randomized controlled trial. JMIR Res Protoc 2017;6:e181.
Hardy RS, Botfield H, Markey K, Mitchell JL, Alimajstorovic Z, Westgate CSJ, et al. 11βHSD1 Inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension. J Clin Endocrinol Metab 2021;106:174–87.
Kobeissi H, Bilgin C, Ghozy S, Adusumilli G, Thurnham J, Hardy N, et al. Common design and data elements reported on idiopathic intracranial hypertension trials: A systematic review. J Neuroophthalmol 2024;44:66–73.
Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Brock K, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension:A randomized clinical trial. Brain 2023;146:1821–30.
Frohman LP. A profile of neuro-ophthalmic practice around the world. J Neuroophthalmol 2018;38:47–51.
Nakamoto CH, Cutler DM, Beaulieu ND, Uscher-Pines L, Mehrotra A. The Impact Of Telemedicine On Medicare Utilization, Spending, And Quality,2019–22. Health Aff (Millwood) 2024;43:691–700.
Patel S, Hamdan S, Donahue S. Optimising telemedicine in ophthalmology during the COVID-19 pandemic. J Telemed Telecare 2022;28:498–501.
Moss HE, Lai KE, Ko MW. Survey of telehealth adoption by neuro-ophthalmologists during the COVID-19 pandemic: Benefits, barriers, and utility. J Neuroophthalmol 2020;40:346–55.
Shen AA, Gutierrez KG, Villegas NC, Moss HE. Evolution of Disparities in Outpatient Ophthalmic Care at a Tertiary Care Center in California at the beginning of and One Year into the COVID-19 Public Health Emergency. Ophthalmic Epidemiol 2024;31:21–30.
Calix R, Grossman SN, Rasool N, Elam AR, Sidhom D, Ugoh P, et al. Practical approach to the tele-neuro-ophthalmology and neuro-otology visits: Instructional videos. J Neuroophthalmol 2021;41:10–2.
Liu YA, Ko MW, Moss HE. Telemedicine for neuro-ophthalmology: Challenges and opportunities. Curr Opin Neurol 2021;34:61–6.
Aguwa UT, Aguwa CJ, Repka M, Moss HE, Lai KE, Ko MW, et al. Teleophthalmology in the era of COVID-19: Characteristics of early adopters at a large academic institution. Telemed J E Health 2021;27:739–46.
Moss HE, Lai KE, Ko MW. Tele-neuro-ophthalmology utilization, availability and attitudes: Update 1 year into the COVID-19 public health emergency. J Neuroophthalmol 2023;43:40–7.
Elam AR, Sidhom D, Ugoh P, Chen EM, Andoh JE, Nwanyanwu K, et al. Disparities in eye care utilization during the COVID-19 pandemic. Am J Ophthalmol 2022;233:163–70.
Chen EM, Andoh JE, Nwanyanwu K. Socioeconomic and demographic disparities in the use of telemedicine for ophthalmic care during the COVID-19 pandemic. Ophthalmology 2022;129:15–25.
Aziz K, Moon JY, Parikh R, Chen EM, Andoh JE, Nwanyanwu K, et al. Association of patient characteristics with delivery of ophthalmic telemedicine during the COVID-19 pandemic. JAMA Ophthalmol 2021;139:1174–82.
Tham YC, Husain R, Teo KYC, Liu YA, Ko MW, Moss HE, et al. New digital models of care in ophthalmology, during and beyond the COVID-19 pandemic. Br J Ophthalmol 2022;106:452–7.
Sathianvichitr K, Lamoureux O, Nakada S, Tang Z, Schmetterer L, Chen C, et al. Through the eyes into the brain, using artificial intelligence. Ann Acad Med Singap 2023;52:88–95.
Wagner SK, Hughes F, Cortina-Borja M, Pontikos N, Struyven R, Liu X, et al. AlzEye: Longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK. BMJ Open 2022;12:e058552.
Cheung CY, Ran AR, Wang S, Chan VTT, Sham K, Hilal S, et al. A deep learning model for detection of Alzheimer’s disease based on retinal photographs: A retrospective, multicentre case-control study. Lancet Digit Health 2022;4:e806-15. doi: 10.1016/S2589-7500(22)00169-8.
Milea D, Najjar RP, Jiang Z, Ting D, Vasseneix C, Xu X, et al. Artificial intelligence to detect papilledema from ocular fundus photographs. N Engl J Med 2020;382:1687–95.
Vasseneix C, Nusivovici S, Xu X, Hwang JM, Hamann S, Chen JJ, et al. Human clinicians are outperformed by a deep learning system for identification of optic disc lesions heralding vision- and life-threatening conditions. J Neuroophthalmol 2022.
Biousse V, Newman NJ, Najjar RP, Vasseneix C, Xu X, Ting DS, et al. Optic disc classification by deep learning versus expert neuro-ophthalmologists. Ann Neurol 2020;88:785–95.
Vasseneix C, Najjar RP, Xu X, Tang Z, Loo JL, Singhal S, et al. Accuracy of a deep learning system for classification of papilledema severity on ocular fundus photographs. Neurology 2021;97:e369–77.
Biousse V, Najjar RP, Tang Z, Lin MY, Wright DW, Keadey MT, et al. Application of a deep learning system to detect papilledema on nonmydriatic ocular fundus photographs in an emergency department. Am J Ophthalmol 2023;S0002-9394(23)00456-7.
Leong YY, Vasseneix C, Finkelstein MT, Milea D, Najjar RP. Artificial intelligence meets neuro-ophthalmology. Asia Pac J Ophthalmol (Phila) 2022;11:111–25.